Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab - Aix-Marseille Université Access content directly
Journal Articles Multiple Sclerosis Journal Year : 2018

Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab

Abstract

Background: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Objective: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male. Methods: Case report. Results: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course. Conclusion: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.

Domains

Immunotherapy
No file

Dates and versions

hal-03538546 , version 1 (21-01-2022)

Identifiers

Cite

Benoit Meunier, Audrey Rico, Julie Seguier, Clemence Boutiere, Mikael Ebbo, et al.. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Multiple Sclerosis Journal, 2018, 24 (6), pp.811-813. ⟨10.1177/1352458517729766⟩. ⟨hal-03538546⟩
7 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More